Suppr超能文献

碳酸镧、醋酸钙与CKD中磷限制的变化:一项随机对照试验

Changes With Lanthanum Carbonate, Calcium Acetate, and Phosphorus Restriction in CKD: A Randomized Controlled Trial.

作者信息

Kovesdy Csaba P, Lu Jun Ling, Wall Barry M, Gyamlani Geeta, Naseer Adnan, Wallick Angela, Han Zhongji, Thomas Fridtjof, Quarles L Darryl, Jarmukli Nabil

机构信息

Nephrology Section, Memphis Veterans Affairs Medical Center, Memphis, Tennessee, USA.

Division of Nephrology, University of Tennessee Health Science Center, Memphis, Tennessee, USA.

出版信息

Kidney Int Rep. 2018 Mar 23;3(4):897-904. doi: 10.1016/j.ekir.2018.03.011. eCollection 2018 Jul.

Abstract

INTRODUCTION

Abnormal phosphorus homeostasis develops early in chronic kidney disease (CKD). It is unclear if its correction results in improved clinical outcomes in non-dialysis dependent CKD.

METHODS

We conducted a randomized controlled, parallel design clinical trial in 120 patients with estimated glomerular filtration rate 15 to 59 ml/min per 1.73 m and abnormal phosphorus homeostasis (serum phosphorus >4.6 mg/dl, parathyroid hormone [PTH] >70 pg/ml or tubular reabsorption of phosphorus [TRP] <80%). Patients were randomized to open-label lanthanum carbonate versus calcium acetate versus dietary intervention over 1 year. The co-primary outcomes were month 12 (vs. baseline) biochemical (serum phosphorus, TRP, PTH, calcium, bone-specific alkaline phosphatase [bALP], and fibroblast growth factor 23 [FGF23]) and vascular parameters (coronary artery calcium score, pulse wave velocity, and endothelial dysfunction) in all patients. Secondary outcomes were between-treatment differences in change for each parameter between month 12 and baseline. All analyses were intention to treat.

RESULTS

Baseline characteristics were similar in the 3 groups. A total of 107 patients (89%) completed 12 months of follow-up. Differences were not significant at month 12 (vs. baseline) for any of the outcomes except bALP (median [25th, 75th] percentile at month 12 versus baseline: 13.8 [10.6, 17.6] vs. 15.8 [12.1, 21.1],  < .001) and FGF23 (132 [99, 216] vs. 133 [86, 189],  = .002). Changes for all outcomes were similar in the 3 arms except for PTH, which was suppressed more effectively by calcium acetate ( < .001).

CONCLUSION

A 1-year intervention to limit phosphorus absorption using dietary restriction or 2 different phosphorus binders resulted in decreased bALP suggesting improved bone turnover, but no other significant changes in biochemical or vascular parameters in patients with CKD stage 3/4. (ClinicalTrials.gov: NCT01357317).

摘要

引言

慢性肾脏病(CKD)早期就会出现磷稳态异常。目前尚不清楚纠正这种异常是否能改善非透析依赖型CKD患者的临床结局。

方法

我们对120例估计肾小球滤过率为每分钟15至59 ml/1.73 m²且磷稳态异常(血清磷>4.6 mg/dl、甲状旁腺激素[PTH]>70 pg/ml或磷肾小管重吸收[TRP]<80%)的患者进行了一项随机对照、平行设计的临床试验。患者被随机分为开放标签的碳酸镧组、醋酸钙组或饮食干预组,为期1年。共同主要结局是所有患者在第12个月(与基线相比)的生化指标(血清磷、TRP、PTH、钙、骨特异性碱性磷酸酶[bALP]和成纤维细胞生长因子23 [FGF23])和血管参数(冠状动脉钙化评分、脉搏波速度和内皮功能障碍)。次要结局是第12个月与基线相比各参数变化的组间差异。所有分析均采用意向性治疗。

结果

3组的基线特征相似。共有107例患者(89%)完成了12个月的随访。除bALP(第12个月与基线相比的中位数[第25、75百分位数]:13.8 [10.6, 17.6] 对 15.8 [12.1, 21.1],P <.001)和FGF23(132 [99, 216] 对 133 [86, 189],P =.002)外,第12个月(与基线相比)的任何结局差异均无统计学意义。除PTH外,3组所有结局的变化相似,醋酸钙对PTH的抑制作用更有效(P <.001)。

结论

采用饮食限制或两种不同的磷结合剂进行为期1年的干预以限制磷吸收,可使bALP降低,提示骨转换改善,但对3/4期CKD患者的生化或血管参数无其他显著变化。(ClinicalTrials.gov:NCT01357317)

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验